US-based pharmaceutical firm Bristol-Myers Squibb (BMS) has completed the acquisition of drug developer Inhibitex in a $2.5bn deal.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
BMS announced that, following a tender offer for Inhibitex stock, the company had acquired approximately 91% of outstanding shares in the company, paying $26 per share.
Inhibitex will become a wholly owned subsidiary of BMS, becoming key to BMS’s strategy to enter the currently-booming hepatitis C market.
Two new hepatitis C drugs, Merck & Co’s Victrelis and Johnson & Johnson/Vertex’s Incivek, were approved last year becoming the first new hepatitis C drugs to be approved in two decades.
Inhibitex currently has three experimental drugs to treat chronic hepatitis C infection in midstage human testing, comprising of INX-189, FV-100 and Aurexis, as well as other hepatitis C treatments in laboratory testing and a proprietary technology, licensed to Pfizer, for the development of a possible staph vaccine.
BMS already has a hepatitis B medication in Baraclude, but has nothing concrete for the treatment of hepatitis C. BMS CEO Lamberto Andreotti did, however, confirm last month that the company has four experimental hepatitis C drugs in development which could be used to complement the Inhibitex compounds.
Image: Bristol-Myers Squibb’s headquarters, located in New York, US. Credit: Bristol-Myers Squibb.
